Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
AstraZeneca PLC AZN
News
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
European Pharma Leaders Push for National Reforms to Boost Investment
AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Correction to AstraZeneca Article
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
FDA Approves AstraZeneca Treatment for Advanced Breast Cancer — Update
AstraZeneca Gets FDA Approval for Breast Cancer Treatment
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
United States